Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.68 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NCK1 | P16333 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21507506 | 0.88 | CYP1A2 (0.59) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 | |
| SCHEMBL12227986 | 0.88 | CYP1A2 (0.59) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 | |
| SCHEMBL8149748 | 0.84 | CYP2A6 (0.54) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 | |
| SCHEMBL8155016 | 0.84 | CYP2A6 (0.54) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 | |
| SCHEMBL8148709 | 0.84 | CYP2A6 (0.54) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 | |
| SCHEMBL8148720 | 0.84 | CYP2A6 (0.54) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 | |
| SCHEMBL6056946 | 0.83 | CYP1A2 (0.87) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 | |
| SCHEMBL2490023 | 0.83 | CYP1A2 (0.87) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 | |
| SCHEMBL6888140 | 0.83 | CYP1A2 (0.87) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 | |
| SCHEMBL2463834 | 0.83 | CYP1A2 (0.87) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11251376-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-02-15 | — | — | US | disclosed |
| US-20190131535-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-05-02 | — | — | US | disclosed |
| US-7198827-B1 | Nematic liquid crystal composition and liquid crystal display device using the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-7198827-B1 | Nematic liquid crystal composition and liquid crystal display device using the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-5403859-A | PHENYLENE-CYCLIC ETHER COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-04-04 | — | — | US | disclosed |
| EP-0375404-B1 | Heterocyclic derivatives | ICI PLC (GB) | 1994-02-09 | — | — | EP | disclosed |
| US-5234950-A | Antiallergens, antiinflammatory agents; cardiovascular disorders, antiarthritic | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-08-10 | — | — | US | disclosed |
| US-5098930-A | Inhibitors of lipoxygenase for treatment of diseases mediated with leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-03-24 | — | — | US | disclosed |
| EP-0375404-A2 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11251376-B2 | Heterocyclic compound and organic light-emitting device including the same | LAGE3, DDT, AOC2 | CYP1A2 30/4885CYP2A6 897/4885TDP1 2051/4885 |
| US-20190131535-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | LAGE3, DDT, AOC2 | CYP1A2 30/4885CYP2A6 897/4885TDP1 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.